Annual report pursuant to Section 13 and 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- 2. Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

3. Significant Strategic Drug Development Collaborations (Details Narrative)

v3.19.1

3. Significant Strategic Drug Development Collaborations (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue	$ 0	$ 7,585,000
Licenses [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue	$ 0	$ 7,500,000
Serum Institute of India Ltd [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Percent ownership in Xenetic	6.70%	7.20%
Pharmsynthez [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Percent ownership in Xenetic	57.10%	61.50%
Pharmsynthez [Member] \| Series B Preferred Stock [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Common stock outstanding	1,500,000
Pharmsynthez [Member] \| Series A Preferred Stock [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Common stock outstanding	970,000
Research, development, license and supply agreement [Member] \| Takeda [Member] \| Licenses [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue		$ 7,500,000
Research, development, license and supply agreement [Member] \| SynBio [Member] \| Co-Development Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue	$ 0	0
License and supply agreements [Member] \| Serum Institute of India Ltd [Member] \| Royalty Revenue [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue	$ 0	$ 0

- Definition

The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.

+ References

No definition available.

+ Details

Name:	us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_PreferredStockSharesOutstanding
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percent ownership in Xenetic

+ References

No definition available.

+ Details

Name:	xbio_PercentOwnershipInXenetic
Namespace Prefix:	xbio_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=xbio_SerumInstituteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=xbio_PharmsynthezMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_SeriesBPreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=xbio_ResearchDevelopmentLicenseSupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=xbio_TakedaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=xbio_SynBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=xbio_CodevelopmentAgrMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=xbio_LicenseAndSupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=xbio_RoyaltyRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: